A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Phase 2
Recruiting
- Conditions
- Geographic AtrophyMacular Degeneration
- Interventions
- Other: Sham Procedure
- First Posted Date
- 2024-10-10
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 311
- Registration Number
- NCT06635148
- Locations
- πͺπΈ
Centro de Oftalmologia Barraquer, Barcelona, Spain
πΉπ·Baskent University Ankara Hospital, Ankara, Turkey
πΊπΈMaine Eye Center, Portland, Maine, United States
A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Phase 2
Active, not recruiting
- Conditions
- Geographic Atrophy
- Interventions
- First Posted Date
- 2023-04-13
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 305
- Registration Number
- NCT05811351
- Locations
- π©πͺ
Medizinische Hochschule Hannover, Hannover, Germany
π©πͺUniversitatsklinikum Schleswig Holstein Kiel, Kiel, Germany
π©πͺUniversitaetsklinikum Leipzig, Leipzig, Germany
Treatment of Advanced Dry Age Related Macular Degeneration With AAVCAGsCD59
- First Posted Date
- 2017-05-09
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 17
- Registration Number
- NCT03144999
- Locations
- πΊπΈ
Ophthalmic Consultants of Boston, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
Β© Copyright 2025. All Rights Reserved by MedPath